Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation

Liver Transplantation

Volumn 19, Issue 10, 2013, Pages 1099-1107

  Howell, Jessica ^a,b   Sawhney, Rohit ^a,b   Testro, Adam ^a   Skinner, Narelle ^c   Gow, Paul ^a,b   Angus, Peter ^a,b   Ratnam, Dilip ^c   Visvanathan, Kumar ^c  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 6; TACROLIMUS; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD56; CALCINEURIN; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIGANDS; LIPOPOLYSACCHARIDES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TACROLIMUS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884898305     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23712     Document Type: Article

References (27)

1. Deng JF, Geng L, Qian YG, Li H, Wang Y, Xie HY, et al. The role of toll-like receptors 2 and 4 in acute allograft rejection after liver transplantation. Transplant Proc 2007; 39: 3222-3224.
2. Chen L, Wang T, Zhou P, Ma L, Yin D, Shen J, et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006; 6: 2282-2291.
3. Land WG,. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005; 79: 505-514.
4. Andrade CF, Waddell TK, Keshavjee S, Liu M,. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 2005; 5: 969-975.
5. Seki E, Brenner DA,. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335.
6. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L Jr, et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 2003; 170: 5615-5624.
7. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
8. Eissens DN, Van Der Meer A, Van Cranenbroek B, Preijers FW, Joosten I,. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant 2010; 10: 1981-1990.
9. Kang YJ, Kusler B, Otsuka M, Hughes M, Suzuki N, Suzuki S, et al. Calcineurin negatively regulates TLR-mediated activation pathways. J Immunol 2007; 179: 4598-4607.
10. Jennings C, Kusler B, Jones PP,. Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immun 2009; 15: 109-120.
11. Puzik A, Schultz C, Iblher P, Müller-Steinhardt M, Härtel C,. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells. Acta Paediatr 2007; 96: 1483-1489.
12. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR,. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001; 75: 6209-6211.
13. Crotta S, Brazzoli M, Piccioli D, Valiante NM, Wack A,. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol 2010; 52: 183-190.
14. Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ,. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004; 76: 1171-1179.
15. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, Corless CL,. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178-1182.
16. Papatheodoridis GV, Patch D, Dusheiko GM, Burroughs AK,. The outcome of hepatitis C virus infection after liver transplantation-is it influenced by the type of immunosuppression? J Hepatol 1999; 30: 731-738.
17. Howell J, Sawhney R, Skinner N, Gow P, Angus P, Ratnam D, Visvanathan K,. Toll-like receptor 3 and 7/8 function is impaired in hepatitis C rapid fibrosis progression post-liver transplantation. Am J Transplant 2013; 13: 943-953.
18. Yoon JC, Shiina M, Ahlenstiel G, Rehermann B,. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 2009; 49: 12-21.
19. Düesberg U, Schneiders AM, Flieger D, Inchauspé G, Sauerbruch T, Spengler U,. Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol 2001; 35: 650-657.
20. Farag MM, Weigand K, Encke J, Momburg F,. Activation of natural killer cells by hepatitis C virus particles in vitro. Clin Exp Immunol 2011; 165: 352-362.
21. Berenguer M, Prieto M, San Juan F, Rayõn JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210.
22. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C,. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10: 1258-1262.
23. Kim RD, Mizuno S, Sorensen JB, Schwartz JJ, Fujita S,. Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation. Dig Dis Sci 2012; 57: 568-572.
24. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K,. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288.
25. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34.
26. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214-1221.
27. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-789.